The short version
The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to vote on whether to recommend seven peptides for inclusion on the Section 503A Bulk Drug Substances List. A favorable vote is significant — but it does not mean compounding pharmacies can legally produce these peptides the next day. Formal notice-and-comment rulemaking follows, and that process takes 12–18 months. The realistic earliest date for 503A compounding pharmacy access is late 2027.
This matters because media coverage of the hearing has consistently overstated what a favorable vote immediately delivers. For practitioners making supply chain decisions and researchers tracking access, the distinction between a committee recommendation and actual regulatory access is the most important thing to understand.
How we got here
In 2023 and 2024, the FDA moved 19 peptides to Category 2 status — effectively prohibiting compounding pharmacies from producing them. The stated intent was patient safety. The practical outcome was the opposite: patient demand didn't diminish, it relocated from licensed compounding pharmacies operating under USP standards to an unregulated gray market of imported bulk API with no meaningful quality controls.
In February 2026, HHS Secretary Robert F. Kennedy Jr. publicly declared the Category 2 reclassifications illegal and announced his intention to restore access. On April 22, 2026, the FDA administratively removed 12 peptides from Category 2. Removal from Category 2 does not authorize compounding — it removes the prohibition. The path to legal compounding access requires PCAC review followed by formal rulemaking.
Removed from Category 2 means the prohibition on compounding has been lifted — but compounding pharmacies still cannot legally produce these compounds until they are formally added to the 503A Bulks List through rulemaking.
Added to 503A Bulks List (what the July hearing moves toward) means compounding pharmacies can legally source and produce these compounds for patients with valid prescriptions. That step requires a favorable PCAC vote followed by completed notice-and-comment rulemaking.
What the July 23–24 hearing is
The Pharmacy Compounding Advisory Committee is an independent expert panel that advises the FDA. Their role at this hearing is to evaluate the evidence for each nominated compound and vote on whether to recommend it for the 503A Bulk Drug Substances List. The committee's recommendation is non-binding — FDA decides whether to act on it.
Seven compounds are scheduled for the July 23–24 hearing. Five additional compounds are scheduled for a second PCAC hearing before the end of February 2027.
| Compound | Primary research areas | Hearing |
|---|---|---|
| BPC-157 | Tissue repair, GI healing, tendon/ligament, neurological | July 23–24 |
| TB-500 (Thymosin Beta-4 fragment) | Wound healing, tissue regeneration, cardiac | July 23–24 |
| KPV | Anti-inflammatory, ulcerative colitis, gut health | July 23–24 |
| MOTS-C | Metabolic regulation, mitochondrial function, longevity | July 23–24 |
| Semax | Cognitive enhancement, neuroprotection, BDNF upregulation | July 23–24 |
| Epitalon | Telomere extension, longevity, pineal regulation | July 23–24 |
| Emideltide (DSIP) | Sleep regulation, opioid withdrawal, stress response | July 23–24 |
| GHK-Cu | Skin repair, wound healing, anti-inflammatory, hair growth | Before Feb 2027 |
| LL-37 (Cathelicidin) | Immune modulation, antimicrobial, wound healing | Before Feb 2027 |
| Dihexa | Cognitive enhancement, neurogenesis, memory | Before Feb 2027 |
| PEG-MGF | Muscle repair, satellite cell activation, recovery | Before Feb 2027 |
| Melanotan II | Melanogenesis, sexual function, appetite suppression | Before Feb 2027 |
The realistic timeline to compounding access
This is where most coverage gets it wrong. A favorable PCAC vote is step one of a multi-step process. Here is what actually has to happen before a compounding pharmacy can legally produce BPC-157 under a physician prescription.
Including BPC-157, TB-500, GHK-Cu, Semax, Epitalon, KPV, MOTS-C, LL-37, Dihexa, PEG-MGF, Melanotan II, and Emideltide. Removal lifts the prohibition but does not authorize compounding.
Committee votes on whether to recommend inclusion on the 503A Bulks List. Non-binding recommendation. FDA then decides whether to initiate rulemaking. This is the step most coverage is focused on.
GHK-Cu, LL-37, Dihexa, PEG-MGF, and Melanotan II reviewed for 503A inclusion. Same process as July hearing.
Following a favorable PCAC vote, FDA publishes a Notice of Proposed Rulemaking in the Federal Register. The public comment period opens — typically 60–90 days. This step alone takes several months after the hearing.
Once the Final Rule is published in the Federal Register, compounding pharmacies can legally source bulk peptide material and prepare finished products under valid prescriptions. This is the earliest realistic date based on historical FDA rulemaking timelines of 12–18 months.
Of all the substances ever nominated for the Section 503A Bulk Drug Substances List, only approximately 10 have ever completed final rulemaking. The process is slower than most people expect. A favorable PCAC vote is necessary but not sufficient for compounding access.
What this means for practitioners
For functional medicine physicians, concierge practitioners, and longevity clinics, the practical implication is straightforward: your patients will continue asking about these compounds regardless of what happens on July 23. A favorable vote does not open a compounding pharmacy channel this year or next. The regulated RUO supply channel remains the only practical access point through at least late 2027.
The gray market consolidation that began in 2025 — with major vendors closing under FDA enforcement pressure — means the supply chain for these compounds is thinner and more variable than it was two years ago. The quality standards that compounding pharmacies will eventually need to meet are exactly what quality-documented RUO suppliers already carry: US-manufactured, cGMP, independent third-party testing for identity, purity, stability, and heavy metals.
What to watch for after the July 24 vote
If the committee votes favorably, the next milestone to track is the Federal Register for a Notice of Proposed Rulemaking. That notice — not the PCAC vote — is what formally begins the countdown to compounding access. Watch for it in Q3 or Q4 2026. We will publish an update here the day it appears.
Revia LLC on the federal record
On June 10, 2026, Revia LLC submitted formal public comments to the FDA's Pharmacy Compounding Advisory Committee in support of 503A inclusion for all seven compounds under July review and the five compounds scheduled for February 2027 review. Our comment argued that quality-documented US suppliers deserve a regulated pathway — and that the 2023–2024 Category 2 restrictions created the unsafe gray market supply chain they were intended to prevent.
Comment tracking number: mq8-c88x-9wb1 · Docket: FDA-2025-N-6895 · Document ID: FDA-2025-N-6895-0001. The comment is publicly accessible at regulations.gov.
This article will be updated with the actual PCAC vote results on July 24, 2026, and again when FDA initiates rulemaking. Check back after the hearing for the updated timeline.
Practitioner accounts — available now
Quality-documented, US 503(b) manufactured peptides for licensed practitioners. Full COA documentation with every order. No minimum order. Wholesale pricing.
Apply for a Practitioner Account →